Annelies Verbiest

Annelies Verbiest

Auto-generated profile, based on publicly available information

Annelies Verbiest

Department of Oncology, Multidisciplinary Oncological Center Antwerp, Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2018 in European Urology
Verified
Journal Article
Closed access
PDF file
AVAnnelies Verbiest
Annelies Verbiest
GCGabrielle Couchy
Gabrielle Couchy
SJSylvie Job
Sylvie Job
LCLaure Caruana
Laure Caruana
ELEvelyne Lerut
Evelyne Lerut
BBBenoit Beuselinck
Benoit Beuselinck

1 November 2014 in Blood Reviews
Verified
Journal Article
Closed access
AVAnnelies Verbiest
Annelies Verbiest
JPJacques Pirenne
Jacques Pirenne
DDDaan Dierickx
Daan Dierickx

1 June 2018 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
AVAnnelies Verbiest
Annelies Verbiest
GCGabrielle Couchy
Gabrielle Couchy
SJSylvie Job
Sylvie Job
JZJessica Zucman-rossi
Jessica Zucman-rossi
LCLaure Caruana
Laure Caruana
BBBenoit Beuselinck
Benoit Beuselinck

21 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
LKLisa Kinget
Lisa Kinget
EREduard Roussel
Eduard Roussel
AVAnnelies Verbiest
Annelies Verbiest
MAMaarten Albersen
Maarten Albersen
Cristina Rodriguez-AntonaCristina Rodriguez-Antona
Cristina Rodriguez-Antona
BBBenoit Beuselinck
Benoit Beuselinck
Metastatic clear-cell renal cell carcinoma (m-ccRCC) is characterized by increased hypoxia-induced factor (HIF)-2α and vascular endothelial growth factor receptor (VEGFR)-dependent angiogenesis through loss of function of the von Hippel–Lindau protein. VEGFR tyrosine kinase inhibitors (VEGFR-TKIs) are a cornerstone of m-ccRCC treatment, and new treatments targeting HIF-2α are currently under investigation. However, predictive biomarkers for these treatments are lacking. In this retrospective cohort study including 109 patients treated with VEGFR-targeted therapies as first-line treatment, we aimed to study the possible predictive function of microRNAs (miRNAs) targeting HIF-2α, VEGFR1 and VEGFR2. We selected miRNAs inversely correlated with HIF-2α, VEGFR1 and/or VEGFR2 expression and with predicted target sites in the respective genes and subsequently studied their impact on therapeutic outcomes. We identified four miRNAs (miR-34c-5p, miR-221-3p, miR-222-3p and miR-3529-3p) inversely correlated with VEGFR1 and/or VEGFR2 expression and associated with tumor shrinkage and progression-free survival (PFS) upon treatment with VEGFR-TKIs, highlighting the potential predictive value of these miRNAs. Moreover, we identified three miRNAs (miR-185-5p, miR-223-3p and miR-3529-3p) inversely correlated with HIF-2α expression and associated with tumor shrinkage and PFS upon treatment with VEGFR-TKIs. These three miRNAs can have a predictive value not only upon treatment with VEGFR-TKIs but possibly also upon treatment with the upcoming HIF-2α inhibitor belzutifan.

1 August 2018 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
AVAnnelies Verbiest
Annelies Verbiest
DLDiether Lambrechts
Diether Lambrechts
TBThomas Van Brussel
Thomas Van Brussel
GCGabrielle Couchy
Gabrielle Couchy
AWAgnieszka Wozniak
Agnieszka Wozniak
BBBenoit Beuselinck
Benoit Beuselinck

28 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
LKLisa Kinget
Lisa Kinget
EREduard Roussel
Eduard Roussel
DLDiether Lambrechts
Diether Lambrechts
BBBram Boeckx
Bram Boeckx
LVLoïc Vanginderhuysen
Loïc Vanginderhuysen
BBBenoit Beuselinck
Benoit Beuselinck
Bone metastasis in clear-cell renal cell carcinoma (ccRCC) leads to substantial morbidity through skeletal related adverse events and implicates worse clinical outcomes. MicroRNAs (miRNA) are small non-protein coding RNA molecules with important regulatory functions in cancer development and metastasis. In this retrospective analysis we present dysregulated miRNA in ccRCC, which are associated with bone metastasis. In particular, miR-23a-3p, miR-27a-3p, miR-20a-5p, and miR-335-3p specifically correlated with the earlier appearance of bone metastasis, compared to metastasis in other organs. In contrast, miR-30b-3p and miR-139-3p were correlated with less occurrence of bone metastasis. These miRNAs are potential biomarkers and attractive targets for miRNA inhibitors or mimics, which could lead to novel therapeutic possibilities for bone targeted treatment in metastatic ccRCC.